AstraZeneca's third-quarter revenue rose 7% to $16.209 billion, while reported earnings per share increased to $2.02, the drugmaker said in its 30 October results. Core EPS, which excludes specified items, was $2.79.
The two earnings measures both improved, but they are not interchangeable. Reported EPS rose 23% at actual exchange rates, compared with 17% growth in core EPS. The results cover the three months ended September; the nine-month columns in the same release cover a longer period.
Read the quarter separately from nine months
Exact primary source checked at 2026-10-31T09:01:17.295Z. Amounts and periods are as labelled below.
| Measure or condition | Verified observation | Primary evidence |
|---|---|---|
| Q3 total revenue | $16.209bn; +7% actual and CER | AstraZeneca PLC issuer announcement distributed through Nasdaq official disclosure service |
| Q3 reported EPS | $2.02; +23% actual / +26% CER | AstraZeneca PLC issuer announcement distributed through Nasdaq official disclosure service |
| Q3 core EPS | $2.79; +17% actual / +19% CER | AstraZeneca PLC issuer announcement distributed through Nasdaq official disclosure service |
| Nine-month revenue | $46.881bn; +8% actual / +7% CER | AstraZeneca PLC issuer announcement distributed through Nasdaq official disclosure service |
| FY2026 outlook | Revenue growth mid-to-high single digits; core EPS growth low double digits, both at CER | AstraZeneca PLC issuer announcement distributed through Nasdaq official disclosure service |
What the core adjustment changes
The issuer summary presents reported EPS and core EPS in separate rows. This report retains those labels instead of treating the higher core figure as reported earnings. The captured summary does not reproduce the full item-by-item reconciliation, so no particular adjustment is attributed here.
Currency also matters. Constant exchange rates, abbreviated CER, remove the effects of currency movements between the comparison periods under the issuer's method. The actual-rate and CER growth percentages should remain labelled, even when they happen to be the same for a particular row.
Guidance remains a forecast
The company reconfirmed its full-year outlook at CER: revenue growth in a mid-to-high single-digit range and core EPS growth in a low-double-digit range. This is not guidance for reported EPS, and it is not a completed result.
The practical follow-up is whether the remaining period delivers the expected growth on the specified basis. Clinical milestones and stated long-term product potential do not establish current revenue, a regulatory outcome or an investment return.
Primary source record
AstraZeneca PLC issuer announcement distributed through Nasdaq official disclosure service — https://attachment.news.eu.nasdaq.com/af5a26f5b3af9be138f05a0f2262f0f8a; observed 2026-10-31T09:01:17.295Z. This is primary-source checking assisted by AI, not independent human editorial approval.
Additional primary record
AstraZeneca PLC — https://www.astrazeneca.com/investor-relations/9m-and-q3-2026-results-event.html; checked 2026-10-31T09:08:17.278Z. Issuer results-event page links the same results announcement; verifies timing and document identity, not an independent numerical confirmation.
Recorded source observation: . This is a source-check timestamp, not a market quote or a new article update.